Roles of capsaicin-sensitive sensory nerves, endogenous nitric oxide, sulfhydryls, and prostaglandins in gastroprotection by momordin Ic, an oleanolic acid oligoglycoside, on ethanol-induced gastric mucosal lesions in rats.
The roles of capsaicin-sensitive sensory nerves (CPSN), endogenous nitric oxide (NO), sulfhydryls (SHs), prostaglandins (PGs) in the gastroprotection by momordin Ic, an oleanolic acid oligoglycoside isolated from the fruit of Kochia scoparia (L.) SCHRAD., on ethanol-induced gastric mucosal lesions were investigated in rats. Momordin Ic (10 mg/kg, p.o.) potentially inhibited ethanol-induced gastric mucosal lesions. The effect of momordin Ic was markedly attenuated by the pretreatment with capsaicin (125 mg/kg in total, s.c., an ablater of CPSN), N(G)-nitro-L-arginine methyl ester (L-NAME, 70 mg/kg, i.p., an inhibitor of NO synthase), N-ethylmaleimide (NEM, 10 mg/kg, s.c., a blocker of SHs), or indomethacin (10 mg/kg, s.c., an inhibitor of PGs biosynthesis). The attenuation of L-NAME was abolished by L-arginine (300 mg/kg, i.v., a substrate of NO synthase), but not by D-arginine (300 mg/kg, i.v., the enatiomer of L-arginine). The effect of the combination of capsaicin with indomethacin, NEM, or L-NAME was not more potent than that of capsaicin alone. The combination of indomethacin and NEM, indomethacin and L-NAME, or indomethacin and NEM and L-NAME increased the attenuation of each alone. These results suggest that CPSN play an important role in the gastroprotection by momordin Ic on ethanol-induced gastric mucosal lesions, and endogenous PGs, NO, and SHs interactively participate, in rats.
Matsuda
H
H
Kyoto Pharmaceutical University, Japan.
Li
Y
Y
Yoshikawa
M
M
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D002211:Capsaicin / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D000431:Ethanol; D005753:Gastric Mucosa / Q000187:drug effects; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000627:therapeutic use; D009475:Neurons, Afferent / Q000187:drug effects / Q000502:physiology*; D009569:Nitric Oxide / Q000502:physiology*; D009828:Oleanolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D011292:Premedication; D011453:Prostaglandins / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013272:Stomach Diseases / Q000139:chemically induced / Q000517:prevention & control*; D013438:Sulfhydryl Compounds / Q000502:physiology*
D000964:Antimetabolites, Antineoplastic; D004791:Enzyme Inhibitors; D011453:Prostaglandins; D013438:Sulfhydryl Compounds; C408362:momordin I (Oleanolic Acid); D009569:Nitric Oxide; D000431:Ethanol; D009828:Oleanolic Acid; D002211:Capsaicin; D019331:NG-Nitroarginine Methyl Ester; D007213:Indomethacin